The Cancer Letter

Inside information on cancer research and drug development

Vol.
34
No.
10
October 28, 2011Oct 28, 2011
Free
DOWNLOAD THE PDF

Herceptin Regimen Minus Adriamycin Increases Survival With Less Toxicity

Alimta Reduces Risk Of Progression In Patients Aged 70 Years or Older

Family History of BRCA Mutation Does Not Equal Increased Risk

Daily Vitamin E Supplements Can Lead to Increased PCa Risk

Digital Immunoassay PSA Test May Predict Cancer Recurrence

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

Researchers Discover Bacteria Common in Colon Cancer Tissue

Colon Cancer Survival Rates Differ Across Racial Lines

NCI Predicts 42 Percent Increase In Number of Senior Survivors

IMRT Less Toxic Than 3D-CRT In Localized Prostate Cancer

NCI CTEP: Approved Trials For The Month of October

FDA Grants Accelerated Approval To Ferriprox for Iron Overload

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account